Nasdaq: Biofrontera's Ameluz SNDA For Superficial Basal Cell Carcinoma Accepted By FDA Nasdaq: Biofrontera Inc. Reports Completion of One-Year Follow-Up in Phase 3 Study for Ameluz in Superficial Basal Cell Carcinoma Biofrontera Inc. announced that the last patient in its Phase 3 study, ALA-BCC-CT013, of Ameluz and RhodoLED PDT for treating superficial basal cell carcinoma (sBCC) completed their one-year follow-up ...

Understanding the Context

Biofrontera Inc. Reports Completion of One-Year Follow-Up in Phase 3 Study for Ameluz in Superficial Basal Cell Carcinoma Ameluz-based photodynamic therapy achieved higher clearance rates in superficial basal cell carcinoma compared to placebo, with significant clinical and histological results. The study involved 187 ... Seeking Alpha: Biofrontera Inc.

Key Insights

Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC) Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC) Seeking Alpha: Biofrontera Inc. Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC) Biofrontera Inc. Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC) Healio: Last patient completes follow-up for phase 3 study of Ameluz-PDT for basal cell carcinoma Last patient completes follow-up for phase 3 study of Ameluz-PDT for basal cell carcinoma Physician's Weekly: Emerging Therapeutic Approaches & Diagnostic Tools for Basal Cell Carcinoma A recent narrative review looks at the most effective and emerging options for diagnosing and treating basal cell carcinoma. Basal Cell Carcinoma: Causes, Symptoms, Diagnosis and Treatment: By Shreoshree Chakrabarty Basal Cell Carcinoma (BCC) is one of the most common skin cancer types, affecting millions globally each year ...

Final Thoughts

Please provide your email address to receive an email when new articles are posted on . AIV001 is a pan-tyrosine kinase inhibitor for the nonsurgical treatment of mixed basal cell carcinomas. Injected ... The Journal News: What causes skin cancer? What to know about basal cell carcinoma and symptoms Gov. Kathy Hochul's recent announcement that she will have a basal cell carcinoma, a common form of skin cancer, removed this week may have many wondering what causes skin cancer and about the most ...

What causes skin cancer? What to know about basal cell carcinoma and symptoms (Miami Beach, Florida) — Basal cell carcinoma, the most common type of skin cancer, can be effectively treated with a radioactive skin patch containing phosphorus 32, researchers said ...